Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Aadi Bioscience, Inc. (ARPO)
|
Add to portfolio |
|
|
|
| Price: |
$24.49
| | Metrics |
| OS: |
24.5
|
M
| |
-47
|
% ROE
|
| Market cap: |
$600
|
M
| |
-91
|
% ROIC
|
|
Net cash:
|
$135
|
M
| |
$5.50
|
per share
|
|
EV:
|
$466
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($66.9)
|
M
| |
|
|
| EPS |
($2.44)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 15.2 | 1.1 | 14.6 | 0.0 | 20.2 | 0.0 | 0.0 | 0.0 |
| Revenue growth | 1258.6% | -92.3% | | -100.0% | | | | |
| Cost of goods sold | 1.3 | 0.6 | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 13.9 | 0.5 | 13.8 | 0.0 | 20.2 | 0.0 | 0.0 | 0.0 |
| Gross margin | 91.2% | 48.4% | 95.0% | | 100.0% | | | |
| Selling, general and administrative | 40.2 | | | | | | | |
| Research and development | 32.7 | 19.7 | 15.0 | 12.8 | 17.9 | 12.1 | 11.4 | |
| General and administrative | | 18.5 | 2.1 | 9.8 | 13.5 | 9.2 | 5.3 | 0.0 |
| EBITA | -62.7 | -37.0 | -2.5 | -24.4 | -11.2 | -21.4 | -16.6 | 0.0 |
| EBITA margin | -411.9% | -3300.5% | -17.5% | | -55.5% | | | |
| Amortization of intangibles | | 0.1 | | | | | | |
| EBIT | -62.7 | -37.1 | -2.5 | -24.4 | -11.2 | -21.4 | -16.6 | 0.0 |
| EBIT margin | -411.9% | -3309.0% | -17.5% | | -55.5% | | | |
| Pre-tax income | -60.5 | -110.1 | -3.5 | -23.3 | -10.4 | -21.4 | -17.0 | 0.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -60.5 | -110.1 | -3.5 | -23.3 | -10.4 | -22.3 | -20.9 | 0.0 |
| Net margin | -397.7% | -9829.5% | -23.9% | | -51.6% | | | |
| |
| Diluted EPS | ($2.69) | ($12.34) | ($1.37) | ($0.57) | ($0.31) | ($1.03) | ($24.53) | ($0.01) |
| Shares outstanding (diluted) | 22.5 | 8.9 | 2.5 | 40.6 | 33.9 | 21.7 | 0.9 | 5.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|